ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

1. InBio Ltd. ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

2. Facts on InBio • Established in Tallinn, 1999 • General business idea: to develop neweffective and selective skin cancertherapeutics and diagnostics. • The company was initiated by a group of scientists of National Institute of Chemical Physics and Biophysics and KarolinskaInstitute, Sweden

3. 1999 2000 2001 Turnover 10000 225000 190000 Profit beforetaxes -2000 19000 8000 Equity 3300 3300 3300 Employees 2 4 7 Financial results (EUR):

4. Background for product development • Cancer is the second most common cause of death in the developed world • The limits of usefulness are being approached for conventional therapies and further advances will require principally new approaches • The foreseen products of our company are prototypes of new anti-cancer drugs that are characterised by: • -high degree of selectivity • -efficient delivery

5. What is antibody? • Antibodies are made by a class of white blood cells • They are naturally present in the blood • Biological function is to perform defence functions • Each antigen causes the formation of a specific antibody • Recombinant DNA technology allows the engineer antibodies • It is possible to produce complete antibodiesin cell culture systems.

6. Reasons to use antibodies in drug development • Can be rationally designed and easily made • Can be engineered to add fragmenmts that enhance their therapeutic potential • Have no intrinsic toxicity as based on the natural molecules • Monoclonal antibodies (mAbs)will not fail at the drug safety testing (phase I clinical trial stages) • Technology is now advanced enough for therapeutic applications of mAbs

7. What is new in our technology? • Our technology combines two different platforms: • Monoclonal antibodies against cancer-specific antigens • Modification of antibody sequence to make these mAbs membrane permeable • Such approach helps to utilise intracellular cancer-specific targets that can not be usually reached • Focus on skin cancer, first targets are GLI proteins

8. What are GLI proteins? • GLI proteins are gene switches • GLI proteins are involved in development and lead cells to divide • Abnormal activation of GLI proteins lead to cancer • GLI proteins represent an attractive target for anticancer drug development

9. Gene switch turned on Cancer develops Cancer development inhibited

10. Cell penetrating peptides (CPPs) • Family of peptides capable to penetrate cellular membranes • We can transport the following molecules into cells using CPP technology: • -other peptides • -nucleic acids • -proteins e.g. antibodies

11. World antibody market: • Currently more than 200 monoclonal antibodies are indevelopment • Targeted disorders include cancer, heart disease, infectious diseases and autoimmunediseases • Market is still in its inception stage, • Market size estimated at nearly $2.8 billion in 1999,

12. World antibody market: • Market forecast growth toalmost $9.8 billion in 2004. • Expected therapeutic antibodyaverage annual growth rate is projected at 21,8% • Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate • Main Target Markets for InBio: • Scandinavian Market • U.S. market

13. Timing and positioning • Antibodybased drugsare in the position of significant commercial growth • InBio enters the market at the moment when all developers seek for new approaches • InBio has new technology to make antibodies more effective • InBio has involved outstanding specialists from all fields that are required to accomplish our business plan

14. Benefits for the investor: • Will invest in profitable business at evolving market • Will invest in area that is significantly improving the well-being of the mankind • Will get possession rights of a unique know-how and new technologies that will realise in new type of therapeutic and diagnostic tools